Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by Boomskidon May 31, 2023 9:14pm
134 Views
Post# 35473996

RE:Biodexa

RE:BiodexaNah, don't agree, poof. I think the whole deal was about the xB3 Platform. Biodexa would have received something for xB3 such as cancellation of the prepaid warrants and then a well-priced financing, based on far less dilution, etc, etc. Biodexa would maybe have kept xB3-licensed drugs for Hunter syndrome, the EGF stuff, maybe the deals with J&J and others.

But the meat would likely have gone to Armistice, or a vehicle supported/owned by the LG placees. If that had happened then Bioasis shareholders may have ultimately had a greater piece of Biodexa (with the pre-paid warrants gone) and then they could have ridden Biodexa to a win of some sort.

But without the xB3 platform. Midatech said that they (as Biodexa) would no longer be a drug delivery company. The big money would be made in private hands with brain tumours, inflammation (maybe), and other neurodegeneration therapeutics.

It can still happen. Bioasis shareholders can still get double digit ownership of Biodexa, but without the xB3 Platform.

I know. I'm repeating myself. And it's all speculation. It's kind of like the entire stock market, isn't it?

jd

<< Previous
Bullboard Posts
Next >>